BiotechTube
Home/Xeris Pharmaceuticals/Steven Prestrelski, Ph.D.
SP

Steven Prestrelski, Ph.D.

Chief Scientific Officer, Co-founder

Xeris Pharmaceuticals

Therapeutic Areas

EndocrinologyNeurologyMetabolic

Xeris Pharmaceuticals Pipeline

DrugIndicationPhase
Gvoke® (glucagon)Severe HypoglycemiaMarketed
Keveyis® (dichlorphenamide)Primary Periodic ParalysisMarketed
Recorlev® (levoketoconazole)Endogenous Cushing’s SyndromeMarketed
XP-8121Undisclosed Metabolic IndicationPhase 2
XP-19986Undisclosed CNS IndicationPhase 1
XP-6341Undisclosed Endocrine IndicationPhase 1

Leadership Team at Xeris Pharmaceuticals

PR
Paul R. Edick
Chairman and Chief Executive Officer
BM
Barry M. Deutsch
Chief Financial Officer
KE
Kenneth E. Johnson, Pharm.D.
Chief Commercial Officer
JP
John P. Schmid
Chief Business Officer
View full Xeris Pharmaceuticals profile